When GLP-1 therapy stops, patients regain about two-thirds of lost weight within 12 months. STEP-1 extension, STEP-4, and SURMOUNT-4 data quantify the rebound.
GLP-1 receptor agonists are weight-management drugs, not weight-loss cures. The STEP-1 extension showed participants regained about two-thirds of lost weight within one year of stopping¹. STEP-4 randomized 803 participants who had completed semaglutide titration to continue or switch to placebo: the continued arm lost an additional 7.9% while placebo regained 6.9%, a 14.8 percentage-point gap². SURMOUNT-4 replicated the pattern for tirzepatide³. The clinical implication is that obesity is a chronic disease and pharmacologic therapy is most appropriately framed as long-term.
STEP-1 extension: one year after discontinuation
After the 68-week core STEP-1 trial, a 52-week extension followed 327 participants who completed the trial and discontinued semaglutide. By week 120, the original semaglutide arm had reverted from −17.3% at week 68 to −5.6% at week 120 from original baseline — regaining two-thirds of prior weight loss¹.
Cardiometabolic improvements achieved during the active phase (waist circumference, blood pressure, HbA1c, lipids) reverted in parallel with weight regain. Trajectory of regain was approximately linear in the first 6 months post-discontinuation, then slowed.
STEP-4: continued vs withdrawal
After 20 weeks of open-label semaglutide titration during which all participants lost a mean 10.6%, 803 participants were randomized to continue semaglutide or switch to placebo for 48 more weeks. Continued semaglutide produced 7.9% additional weight loss; placebo-switched participants regained 6.9%². The 14.8 percentage-point difference quantifies the cost of discontinuation.
SURMOUNT-4: tirzepatide withdrawal
SURMOUNT-4 used the same design with tirzepatide. After 36 weeks of open-label tirzepatide (mean 20.9% weight loss), 670 participants were randomized to continue or switch to placebo for 52 weeks. Continued tirzepatide lost an additional 5.5%; placebo-switched regained 14.0%³. The magnitude of regain on withdrawal was substantial and rapid.
Mechanisms driving regain
Three convergent mechanisms: (1) appetite-suppressing effects of GLP-1/GIP agonism end within 4-5 half-lives (~5 weeks for semaglutide); (2) weight loss reduces resting energy expenditure beyond what fat-free mass loss alone predicts — the adaptive thermogenesis phenomenon&sup4;; (3) levels of orexigenic hormones (ghrelin) rise and anorexigenic hormones (leptin, PYY) fall after weight loss, biasing energy intake upward. The combined effect: the new lower body weight is metabolically defended at a lower set point.
Maintenance strategies
The Endocrine Society and AACE position obesity as a chronic relapsing disease requiring chronic therapy&sup5;. Three strategies emerge from current evidence: (1) continued full-dose therapy long-term; (2) dose reduction to a maintenance dose once goal weight is achieved (under investigation in STEP-Maintain); (3) intermittent dosing (currently investigational). Patients who must discontinue benefit from intensified behavioral support during the transition: protein-prioritized eating, resistance training, structured weighing routines, and clinical follow-up in the first 3-6 months when regain is most rapid.
Editor's Pick · #1 of 10
NexLife — Semaglutide Program
Editor's PickPhysician-led503A pharmacyAll 50 states
How much weight will I regain if I stop semaglutide?
About two-thirds of the weight lost during active treatment is regained within 12 months of discontinuation, on average. Individual variation is substantial.
Can I take a lower maintenance dose instead?
Lower-dose maintenance strategies are being studied. In current practice, some physicians taper semaglutide to 1.0-1.7 mg after a year. Evidence quality is moderate and developing.
Why is the weight so hard to keep off?
Weight loss reduces resting energy expenditure and shifts appetite hormones (ghrelin up, leptin and PYY down) in directions that promote regain. The drug counteracts these signals while in the system.
Is intermittent dosing a viable strategy?
Currently investigational. Randomized data at scale do not yet exist; current guidelines do not endorse intentional treatment breaks.
How long should I plan to take a GLP-1?
Most obesity specialists frame pharmacotherapy as indefinite, analogous to antihypertensive therapy. Permanent discontinuation typically results in substantial regain.
References
Wilding JPH, Batterham RL, Davies M, et al.Weight regain and cardiometabolic effects after withdrawal of semaglutide: STEP 1 trial extension.Diabetes Obes Metab. 2022;24(8):1553-1564.PMID: 35441470
Rubino D, Abrahamsson N, Davies M, et al.Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance: STEP 4.JAMA. 2021;325(14):1414-1425.PMID: 33755728
Aronne LJ, Sattar N, Horn DB, et al.Continued Treatment With Tirzepatide for Maintenance of Weight Reduction: SURMOUNT-4.JAMA. 2024;331(1):38-48.PMID: 38078870
Fothergill E, Guo J, Howard L, et al.Persistent metabolic adaptation 6 years after "The Biggest Loser" competition.Obesity. 2016;24(8):1612-1619.PMID: 27136388
Garvey WT, Mechanick JI, Brett EM, et al.AACE/ACE comprehensive clinical practice guidelines for medical care of patients with obesity.Endocr Pract. 2016;22(Suppl 3):1-203.PMID: 27219496
Citations are peer-reviewed where available. PubMed (PMID) links resolve to NCBI's PubMed. FDA links resolve to fda.gov. All citations were last verified 2026-05-11.
SS
Lead Medical Researcher
Dr. Sam Saberian, PharmD
Doctor of Pharmacy; leads protocol research, peptide pharmacology, and clinical trial review.
AS
Medical Reviewer
Alen A. Schwartz, MD
Board-certified physician; reviews clinical accuracy of every published page.
JE
Edited by
Julliana Edwards
Editorial standards, factual accuracy, and corrections workflow.